PE20001034A1 - Desnaturalizantes para las sales aminas simpaticomimeticas - Google Patents

Desnaturalizantes para las sales aminas simpaticomimeticas

Info

Publication number
PE20001034A1
PE20001034A1 PE1999000908A PE00090899A PE20001034A1 PE 20001034 A1 PE20001034 A1 PE 20001034A1 PE 1999000908 A PE1999000908 A PE 1999000908A PE 00090899 A PE00090899 A PE 00090899A PE 20001034 A1 PE20001034 A1 PE 20001034A1
Authority
PE
Peru
Prior art keywords
inhibitor
compounds
sympathomimetic amine
water
polymers
Prior art date
Application number
PE1999000908A
Other languages
English (en)
Inventor
William Michael Nichols
William S Bess
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20001034A1 publication Critical patent/PE20001034A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE a)UNA SAL ACIDA DE UNA AMINA SIMPATICOMIMETICA TAL COMO CLORHIDRATO O SULFATO DE PSEUDOEFEDRINA, CLORHIDRATO DE EFEDRINA O DE FENILPROPANILAMINA; b)UN INHIBIDOR DE COMBINACION TAL COMO SALES DE METAL DE TRANSICION (CLORURO, OXIDO, SULFATO O GLUCONATO DE HIERRO, COBALTO, COBRE, MANGANESO, NIQUEL O ZINC) Y POLIMEROS AMINO EN FORMA DE SAL NEUTRALIZADA TAL COMO COPOLIMERO DE METIL, BUTIL O DIMETILAMINOETIL METACRILATO; c)UN INHIBIDOR DE REACCION TAL COMO COMPUESTOS DE POLIHIDROXI INSOLUBLES EN AGUA, POLIHIDROXI NO POLIMEROS SOLUBLES EN AGUA, COMPUESTOS DE ESTER SOLUBLES EN ESTER; d)UN INHIBIDOR DE SEPARACION TAL COMO COMPUESTOS DE CELULOSA SOLUBLE EN AGUA, GOMAS POLISACARIDAS, POLIMEROS DE OXIDO DE POLIETILENO, POLIMEROS DE ACIDO ACRILICO, ALMIDONES, SILICATOS DE ALUMINIO Y MAGNESIO; POLIVINILPIRROLIDONAS Y ARCILLAS; SE CARACTERIZA PORQUE EL INHIBIDOR DE COMBINACION, DE REACCION E INHIBIDOR DE SEPARACION SE PRESENTAN EN CANTIDADES SUFICIENTES PARA INTERFERIR CON EL AISLAMIENTO O CON LA CONVERSION DE DICHA AMINA SIMPATICOMIMETICA EN OTROS COMPUESTOS FARMACOLOGICAMENTE ACTIVOS TAL COMO METANFETAMINA, ANFETAMINA, METCATINONA, CATINONA; SIN ALTERAR SIGNIFICATIVAMENTE LA LIBERACION DE DICHA AMINA SIMPATICOMIMETICA DE LA COMPOSICION EN COMPARACION CON LA COMPOSICION DESNATURALIZADA
PE1999000908A 1998-09-10 1999-09-09 Desnaturalizantes para las sales aminas simpaticomimeticas PE20001034A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9971298P 1998-09-10 1998-09-10

Publications (1)

Publication Number Publication Date
PE20001034A1 true PE20001034A1 (es) 2000-10-18

Family

ID=22276270

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000908A PE20001034A1 (es) 1998-09-10 1999-09-09 Desnaturalizantes para las sales aminas simpaticomimeticas

Country Status (22)

Country Link
US (4) US6359011B1 (es)
EP (1) EP1112089A1 (es)
JP (1) JP2002524534A (es)
KR (1) KR20010075021A (es)
CN (1) CN1201822C (es)
AR (1) AR032730A1 (es)
AU (2) AU771194B2 (es)
BR (1) BR9913575A (es)
CA (1) CA2339354A1 (es)
CO (1) CO5280050A1 (es)
CR (1) CR6106A (es)
GT (1) GT199900148A (es)
HK (1) HK1039898A1 (es)
HN (1) HN1999000156A (es)
MY (1) MY117971A (es)
NZ (1) NZ510012A (es)
PA (1) PA8481601A1 (es)
PE (1) PE20001034A1 (es)
SV (1) SV1999000148A (es)
TW (1) TW550071B (es)
UY (1) UY25702A1 (es)
WO (1) WO2000015261A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199900148A (es) * 1998-09-10 2001-02-28 Desnaturalizantes para las sales aminas simpaticomimeticas.
HUP0303700A3 (en) * 2000-07-17 2006-07-28 Astellas Pharma Inc Chuo Ku Pharmaceutical composition improved in peroral absorbability
PT1920763E (pt) * 2000-11-30 2014-06-25 Vectura Ltd Composições farmacêuticas para inalação
ITMI20021074A1 (it) * 2002-05-20 2003-11-20 Actimex S R L Composizione ternaria comprendente una sostanza attiva e processo di comacinazione per la sua preparazione
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US20050220877A1 (en) * 2004-03-31 2005-10-06 Patel Ashish A Bilayer tablet comprising an antihistamine and a decongestant
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004045037A1 (de) * 2004-09-15 2006-03-16 Basf Ag Pharmazeutische Darreichungsformen mit erschwerter Extrahierbarkeit eines Sympathomimetikums aus der Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US9198865B2 (en) 2006-01-19 2015-12-01 Dow Global Technologies Llc Biologically active composition comprising ethylcellulose
US9238073B2 (en) * 2006-04-12 2016-01-19 Wyeth Llc Pharmaceutical composition containing sympathomimetic amine salt and co-distillable additive
US8273798B2 (en) * 2007-06-04 2012-09-25 Shear Kershman Laboratories Tamper resistant lipid-based oral dosage form for opioid agonists
CA2731801C (en) * 2007-07-23 2013-11-26 Kingsway Pharmaceuticals Inc. Therapeutic formulations for the treatment of cold and flu-like symptoms
JP4879351B2 (ja) 2007-10-19 2012-02-22 大塚製薬株式会社 医薬固形製剤
RU2567723C2 (ru) 2009-07-22 2015-11-10 Грюненталь Гмбх Стабильная при окислении, прочная на излом лекарственная форма
CA2775890C (en) * 2009-09-30 2016-06-21 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
DK2736497T3 (da) 2011-07-29 2017-11-13 Gruenenthal Gmbh Stød-resistent tablet, der tilvejebringer en øjeblikkelig frigivelse af et lægemiddel.
CA2839123A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
WO2013036567A2 (en) * 2011-09-07 2013-03-14 Johnson Brent A Methods, compositions, and compounds for the reduction of illegal methamphetamine production
US20150238615A1 (en) * 2011-12-12 2015-08-27 Leonard Mackles Denaturants for sympathomimetic amines
CA2880163A1 (en) * 2012-08-01 2014-02-06 Acura Pharmaceuticals, Inc. Stabilization of one-pot methamphetamine synthesis systems
MX366159B (es) 2012-11-30 2019-07-01 Acura Pharmaceuticals Inc Liberacion autorregulada de ingrediente farmaceutico activo.
EP3016645A4 (en) * 2013-07-03 2016-12-21 Acura Pharmaceuticals Inc PROCEDURE AND COMPOSITIONS FOR DETECTING FROM ABUSE
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
MX371372B (es) 2013-11-26 2020-01-28 Gruenenthal Gmbh Preparacion de una composicion farmaceutica en polvo por medio de criomolienda.
AU2015237723B2 (en) 2014-03-26 2018-04-26 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release biphasic matrix solid dosage form
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
CA2998259A1 (en) * 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations
TW202002957A (zh) 2018-02-09 2020-01-16 德商歌林達有限公司 包含轉化抑制劑之麻黃素及其衍生物之抗損壞調配物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3169092A (en) 1963-09-26 1965-02-09 Richardson Merrell Inc Stabilization of amines by tartrazine and bisulfite
US3546142A (en) * 1967-01-19 1970-12-08 Amicon Corp Polyelectrolyte structures
US3773920A (en) * 1971-07-14 1973-11-20 Nikken Chemicals Co Ltd Sustained release medicinal composition
GB1593261A (en) 1976-07-23 1981-07-15 Inveresk Res Int Controlled release suppository
RO68771A2 (ro) * 1976-08-25 1980-08-15 Intreprinderea De Medicamente,Ro Unguent antipruriginos si sicativ
SU1146046A1 (ru) 1983-11-11 1985-03-23 Центральный Ордена Ленина Институт Усовершенствования Врачей Состав дл ретракции десны
US4493827A (en) 1983-11-14 1985-01-15 Ronald Valle Method of inducing sleep
US4657757A (en) 1985-03-29 1987-04-14 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
US4601894A (en) * 1985-03-29 1986-07-22 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US4894239A (en) 1987-06-02 1990-01-16 Takeda Chemical Industries, Ltd. Sustained-release preparation and production thereof
ZA904021B (en) 1989-11-24 1991-02-27 Van Der Linde Leon Slimming preparations
CA2068402C (en) 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
NZ267002A (en) 1993-06-04 1997-07-27 Warner Lambert Co Chewable cold/sinus relief preparation comprising antihistamine and decongestant in a carrier consisting of silicon dioxide
US5543405A (en) 1993-10-22 1996-08-06 Keown; Wendy J. Composition and method for weight reduction and long term management of obesity
AUPM814994A0 (en) 1994-09-14 1994-10-06 Sterling Winthrop Inc. Codeine-containing formulations
US5529783A (en) 1994-12-19 1996-06-25 Mcneil-Ppc, Inc. Rotor granulation and coating of acetaminophen, pseudoephedrine, chlorpheniramine, and, optionally dextromethorphan
US5626878A (en) 1995-01-10 1997-05-06 Warner Lambert Company Reduction of electrostatic forces between magnesium trisilicate adsorbates
PT894010E (pt) 1996-04-10 2003-11-28 Warner Lambert Co Desnaturantes para sais de amina simpaticomimetica
GT199900148A (es) * 1998-09-10 2001-02-28 Desnaturalizantes para las sales aminas simpaticomimeticas.

Also Published As

Publication number Publication date
GT199900148A (es) 2001-02-28
US20060216268A1 (en) 2006-09-28
TW550071B (en) 2003-09-01
EP1112089A1 (en) 2001-07-04
AU5915799A (en) 2000-04-03
UY25702A1 (es) 1999-11-17
AU771194B2 (en) 2004-03-18
PA8481601A1 (es) 2001-04-30
CN1316911A (zh) 2001-10-10
JP2002524534A (ja) 2002-08-06
AU2004202702B2 (en) 2007-11-22
NZ510012A (en) 2002-11-26
US6359011B1 (en) 2002-03-19
MY117971A (en) 2004-08-30
SV1999000148A (es) 2000-09-11
HK1039898A1 (zh) 2002-05-17
WO2000015261A1 (en) 2000-03-23
CR6106A (es) 2003-12-05
US20050256194A1 (en) 2005-11-17
KR20010075021A (ko) 2001-08-09
CO5280050A1 (es) 2003-05-30
CN1201822C (zh) 2005-05-18
AR032730A1 (es) 2003-11-26
AU2004202702A1 (en) 2004-07-15
BR9913575A (pt) 2001-05-22
CA2339354A1 (en) 2000-03-23
HN1999000156A (es) 2003-08-01
US20020082304A1 (en) 2002-06-27

Similar Documents

Publication Publication Date Title
PE20001034A1 (es) Desnaturalizantes para las sales aminas simpaticomimeticas
HUP0500736A2 (hu) A nitrogén (II)-oxid szintáz inhibitor hatású (S)-2-amino-4-(2-etánimidoilamino-etiltio)-vajsav-foszfátsó, eljárás előállítására és az ezt tartalmazó gyógyszerkészítmény
GB0018828D0 (en) Alkyl Amino Acid Derivatives useful as pharmaceutical agents
DOP2002000392A (es) Sales tartrato de 5,8,14 triazatetraciclo [10.3.1.024 0.4.9] hexadeca-2 (11), 3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas
BR0015567A (pt) Compostos de ácido fenoxicarboxìlico e composições para liberar agentes ativos
RS51213B (sr) Farmaceutski vaginalni gel koji sadrži tenofovir
PE20050822A1 (es) Derivados de florfenicol con mejor solubilidad en agua
BR0214199A (pt) Composições de fenóxi amina para liberar agentes ativos, forma de unidade de dosagem e método de administração
WO2001012233A3 (en) Sustained release formulation of a peptide
WO2005054179A3 (en) Hydroxamic acid esters and pharmaceutical use thereof
JP2008546809A5 (es)
EP1340755A4 (en) AGENT WITH EFFECT AGAINST HELICOBACTER
WO2001064645A3 (en) Derivatives of quinoline as alpha-2 antagonists
WO2005123049A3 (en) A pharmaceutical composition for increasing the mitochondrial genesis
HN2000000031A (es) Inhibidores de acido abierto y sales de dihidrolixilo de redustosa hmg-co-a.
HRPK20040372B3 (en) Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist
UA93529C2 (ru) Соли и смеси 9-оксоакридин-10-уксусной кислоты c 1-алкиламино-1-дезоксиполиолами
WO2008102349A3 (en) Terbinafine formulation for iontophoresis
MXPA04003540A (es) Utilizacion de un copolimero para producir una forma galenica que contiene un peptido o proteina como agente activo.
EA201000701A1 (ru) 4-[4-(2-адамантилкарбамоил)-5-трет-бутилпиразол-1-ил]бензойная кислота-465
AR044175A1 (es) Compuestos de cefemo
AR079299A1 (es) Mejora de los procesos para la preparacion de granulos solubles de las sales de los acidos carboxilicos que contienen piridina
CA2553231A1 (en) Amine salt of carbostyril derivative
CO4950550A1 (es) Procedimiento
EP1325918A4 (en) CARDIOUS CELL APOPTOSIS INHIBITORS AND TREATMENT / PREVENTION OF HEART DISEASES

Legal Events

Date Code Title Description
FC Refusal